10.3389/fgene.2019.00815.s001
Maria Amorim
Maria
Amorim
João Lobo
João
Lobo
Mário Fontes-Sousa
Mário
Fontes-Sousa
Helena Estevão-Pereira
Helena
Estevão-Pereira
Sofia Salta
Sofia
Salta
Paula Lopes
Paula
Lopes
Nuno Coimbra
Nuno
Coimbra
Luís Antunes
Luís
Antunes
Susana Palma de Sousa
Susana Palma
de Sousa
Rui Henrique
Rui
Henrique
Carmen Jerónimo
Carmen
Jerónimo
DataSheet_1_Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer.docx
Frontiers
2019
Breast cancer
luminal subtype
endocrine therapy
endocrine resistance
biomarkers
microRNAs
2019-09-11 12:50:24
Dataset
https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Predictive_and_Prognostic_Value_of_Selected_MicroRNAs_in_Luminal_Breast_Cancer_docx/9804758
<p>Breast cancer (BrC) is the most frequent malignancy and the leading cause of cancer death among women worldwide. Approximately 70% of BrC are classified as luminal-like subtype, expressing the estrogen receptor. One of the most common and effective adjuvant therapies for this BrC subtype is endocrine therapy. However, its effectiveness is limited, with relapse occurring in up to 40% of patients. Because microRNAs have been associated with several mechanisms underlying endocrine resistance and sensitivity, they may serve as predictive and/or prognostic biomarkers in this setting. Hence, the main goal of this study was to investigate whether miRNAs deregulated in endocrine-resistant BrC may be clinically relevant as prognostic and predictive biomarkers in patients treated with adjuvant endocrine therapy. A global expression assay allowed for the identification of microRNAs differentially expressed between luminal BrC patients with or without recurrence after endocrine adjuvant therapy. Then, six microRNAs were chosen for validation using quantitative reverse transcription polymerase chain reaction in a larger set of tissue samples. Thus, miR-30c-5p, miR-30b-5p, miR-182-5p, and miR-200b-3p were found to be independent predictors of clinical benefit from endocrine therapy. Moreover, miR-182-5p and miR-200b-3p displayed independent prognostic value for disease recurrence in luminal BrC patients after endocrine therapy. Our results indicate that selected miRNAs’ panels may constitute clinically useful ancillary tools for management of luminal BrC patients. Nevertheless, additional validation, ideally in a multicentric setting, is required to confirm our findings.</p>